Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the Group has recently received the notice of acceptance issued by National Medical Products Administration, pursuant to which the clinical trial application for its self-developed novel adjuvanted recombinant shingles vaccine REC610 has been accepted.
